Flamingo

Flamingo Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of novel RNA-targeted therapies for oncology. The company focuses on long non-coding RNAs (lncRNAs), a large and largely untapped class of genes that play critical roles in disease progression. Its lead program, danvatirsen, is an antisense oligonucleotide targeting STAT3, currently being evaluated in Phase 2 clinical trials for head and neck squamous cell carcinoma. Flamingo's pipeline also includes programs targeting MALAT1 and other undisclosed lncRNA targets. By leveraging its proprietary platform and expertise in RNA biology, the company aims to provide transformative treatments for patients with difficult-to-treat cancers.